Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)

Amneal Pharmaceuticals, Inc. is a diversified global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines.

The company generates revenue primarily through the sale of generic pharmaceuticals, injectables, and biosimilars in its Affordable Medicines segment, branded central nervous system and endocrine disorder treatments in its Specialty segment, and distribution of pharmaceuticals and related products to U. S. government agencies and institutional customers through its AvKARE segment.

The company operates through the following segments: Affordable Medicines, Specialty, and AvKARE.

• Affordable Medicines: This segment includes over 280 product families covering generics, injectables, biosimilars, and other dosage forms, with a focus on high‑barrier‑to‑entry products such as first‑to‑file and first‑to‑market opportunities, and maintains a pipeline of 61 pending ANDAs and 43 developmental projects as of December 31, 2025.

• Specialty: This segment promotes branded pharmaceuticals targeting central nervous system and endocrine disorders, featuring products such as CREXONT®, RYTARY®, UNITHROID®, and Brekiya®, and relies on a dedicated sales force that engages neurologists, endocrinologists, and primary care physicians across the United States.

• AvKARE: This segment distributes pharmaceuticals primarily to U. S. Department of Defense and Veterans Affairs facilities, re‑packages and wholesales drugs and medical supplies to retail and institutional customers, and serves organizations that provide care to low‑income and uninsured patients.

Amneal Pharmaceuticals, Inc. holds a competitive position in the generic and biosimilar markets, facing rivals such as Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz Group, and Fresenius Kabi, while its advantages include a vertically integrated supply chain, expertise in complex formulations, and a growing biosimilar portfolio that includes five approved products in the United States as of late 2025.

The company serves a broad customer base that includes major wholesalers and distributors such as Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc., and CVS Health Corporation, which together represented approximately 71% of consolidated net revenue in 2025, along with roughly 1,300 additional customers comprising retail pharmacies, hospitals, government agencies, and institutional providers.